{"title":"特比萘芬与氟康唑治疗体癣疗效比较","authors":"A. Mustafa, S. Hussain, G. Shaheen","doi":"10.29054/APMC/2021.780","DOIUrl":null,"url":null,"abstract":"Background: Tinea corporis is a worldwide superficial fungal infection that mimics many other annular lesions. As the Tinea Corporis have a significant impact on patient’s life physically and psychologically. So, physicians must have knowledge about this condition and its treatment options. Objective: To compare the efficacy of terbinafine versus fluconazole in patients of tinea corporis. Study Design: It was a randomized controlled trial. Settings: Research was conducted at Department of Pharmacology Duration: for a period of 6 months from 10 Feb to 10 Aug 2020 at Khalifa Gulnawaz Teaching Hospital, Bannu, Khyber Pakhtunkhwa & DHQ Teaching Hospital, Bannu, Khyber Pakhtunkhwa Pakistan. Methodology: From both the genders 102 patients aged between 20-45 years who presented with tinea corporis were included in the study. Two treatment groups were made by random allocation of patients. Patients in Group-A were treated with oral terbinafine while those in Group-B were given fluconazole. Frequency of efficacy being outcome variable was labeled upon complete resolution of the tinea corporis in 4 weeks (counted from start of treatment) and was compared between the groups. An informed written informed consent was taken from all the patients. Results: The patients had a mean age of 31.66±6.99 years while the mean duration of disease was 5.41±2.16 months. There were 55 (53.9%) male and 47 (46.1%) female patients with a male to female ratio of 1.2:1. The frequency of efficacy was significantly higher in patients treated with terbinafine as compared to fluconazole (90.2% vs. 64.7%; p-value=0.002). This difference was same in all subgroups as well. Conclusion: Oral terbinafine was found more efficacious than conventional treatment with oral fluconazole in patients with tinea corporis regardless of patient’s age, gender and duration of disease which advocates preferred use of terbinafine in the treatment of such patients in future practice.","PeriodicalId":319424,"journal":{"name":"Annals of Punjab Medical College","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Efficacy of Terbinafine and Fluconazole in Patients of Tinea Corporis\",\"authors\":\"A. Mustafa, S. Hussain, G. Shaheen\",\"doi\":\"10.29054/APMC/2021.780\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Tinea corporis is a worldwide superficial fungal infection that mimics many other annular lesions. As the Tinea Corporis have a significant impact on patient’s life physically and psychologically. So, physicians must have knowledge about this condition and its treatment options. Objective: To compare the efficacy of terbinafine versus fluconazole in patients of tinea corporis. Study Design: It was a randomized controlled trial. Settings: Research was conducted at Department of Pharmacology Duration: for a period of 6 months from 10 Feb to 10 Aug 2020 at Khalifa Gulnawaz Teaching Hospital, Bannu, Khyber Pakhtunkhwa & DHQ Teaching Hospital, Bannu, Khyber Pakhtunkhwa Pakistan. Methodology: From both the genders 102 patients aged between 20-45 years who presented with tinea corporis were included in the study. Two treatment groups were made by random allocation of patients. Patients in Group-A were treated with oral terbinafine while those in Group-B were given fluconazole. Frequency of efficacy being outcome variable was labeled upon complete resolution of the tinea corporis in 4 weeks (counted from start of treatment) and was compared between the groups. An informed written informed consent was taken from all the patients. Results: The patients had a mean age of 31.66±6.99 years while the mean duration of disease was 5.41±2.16 months. There were 55 (53.9%) male and 47 (46.1%) female patients with a male to female ratio of 1.2:1. The frequency of efficacy was significantly higher in patients treated with terbinafine as compared to fluconazole (90.2% vs. 64.7%; p-value=0.002). This difference was same in all subgroups as well. Conclusion: Oral terbinafine was found more efficacious than conventional treatment with oral fluconazole in patients with tinea corporis regardless of patient’s age, gender and duration of disease which advocates preferred use of terbinafine in the treatment of such patients in future practice.\",\"PeriodicalId\":319424,\"journal\":{\"name\":\"Annals of Punjab Medical College\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Punjab Medical College\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29054/APMC/2021.780\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Punjab Medical College","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29054/APMC/2021.780","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:体癣是一种世界性的浅表真菌感染,类似于许多其他环形病变。由于体癣对患者的生理和心理生活都有重大影响。因此,医生必须了解这种情况及其治疗方案。目的:比较特比萘芬与氟康唑治疗体癣的疗效。研究设计:随机对照试验。时间:2020年2月10日至8月10日,在巴基斯坦开伯尔-普赫图赫瓦省班努的Khalifa Gulnawaz教学医院和开伯尔-普赫图赫瓦省班努的DHQ教学医院进行为期6个月的研究。方法:102例年龄在20-45岁之间出现体癣的男女患者被纳入研究。随机分配患者分为两个治疗组。a组患者口服特比萘芬,b组患者口服氟康唑。在4周内(从治疗开始算起)体癣完全消退时,将疗效频次作为结果变量进行标记,并在两组之间进行比较。所有患者均获得知情同意书。结果:患者平均年龄31.66±6.99岁,平均病程5.41±2.16个月。男性55例(53.9%),女性47例(46.1%),男女比例为1.2:1。与氟康唑相比,特比萘芬治疗的患者有效频率显著更高(90.2% vs. 64.7%;假定值= 0.002)。这种差异在所有亚组中也是相同的。结论:口服特比萘芬治疗体癣,不论患者年龄、性别、病程长短,均优于口服氟康唑治疗,建议在今后的实践中优先使用特比萘芬治疗体癣。
Comparison of Efficacy of Terbinafine and Fluconazole in Patients of Tinea Corporis
Background: Tinea corporis is a worldwide superficial fungal infection that mimics many other annular lesions. As the Tinea Corporis have a significant impact on patient’s life physically and psychologically. So, physicians must have knowledge about this condition and its treatment options. Objective: To compare the efficacy of terbinafine versus fluconazole in patients of tinea corporis. Study Design: It was a randomized controlled trial. Settings: Research was conducted at Department of Pharmacology Duration: for a period of 6 months from 10 Feb to 10 Aug 2020 at Khalifa Gulnawaz Teaching Hospital, Bannu, Khyber Pakhtunkhwa & DHQ Teaching Hospital, Bannu, Khyber Pakhtunkhwa Pakistan. Methodology: From both the genders 102 patients aged between 20-45 years who presented with tinea corporis were included in the study. Two treatment groups were made by random allocation of patients. Patients in Group-A were treated with oral terbinafine while those in Group-B were given fluconazole. Frequency of efficacy being outcome variable was labeled upon complete resolution of the tinea corporis in 4 weeks (counted from start of treatment) and was compared between the groups. An informed written informed consent was taken from all the patients. Results: The patients had a mean age of 31.66±6.99 years while the mean duration of disease was 5.41±2.16 months. There were 55 (53.9%) male and 47 (46.1%) female patients with a male to female ratio of 1.2:1. The frequency of efficacy was significantly higher in patients treated with terbinafine as compared to fluconazole (90.2% vs. 64.7%; p-value=0.002). This difference was same in all subgroups as well. Conclusion: Oral terbinafine was found more efficacious than conventional treatment with oral fluconazole in patients with tinea corporis regardless of patient’s age, gender and duration of disease which advocates preferred use of terbinafine in the treatment of such patients in future practice.